2158267-70-8 Usage
Pyrazole derivative
The compound is based on a pyrazole ring, which is a five-membered heterocyclic ring containing one nitrogen atom and one non-aromatic ring.
Dioxaborolane moiety
The compound contains a 1,3,2-dioxaborolan ring, which is a three-membered boron-containing ring with two oxygen atoms.
Potential applications in organic synthesis
Due to its unique structure and functional groups, the compound can be used as a building block for synthesizing novel organic compounds.
Potential applications in medicinal chemistry
The compound may serve as a precursor for the development of pharmaceutical agents, contributing to the creation of new drugs.
Valuable tool for exploring chemical reactions and mechanisms
The compound's unique structure and reactivity make it useful for studying various chemical reactions and mechanisms in the laboratory.
Contribution to scientific and industrial endeavors
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-3-carbonitrile has the potential to advance various fields, including organic synthesis, medicinal chemistry, and chemical research.
Check Digit Verification of cas no
The CAS Registry Mumber 2158267-70-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 2,1,5,8,2,6 and 7 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 2158267-70:
(9*2)+(8*1)+(7*5)+(6*8)+(5*2)+(4*6)+(3*7)+(2*7)+(1*0)=178
178 % 10 = 8
So 2158267-70-8 is a valid CAS Registry Number.
2158267-70-8Relevant academic research and scientific papers
PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA
-
Page/Page column 90-91, (2019/07/13)
Provided herein is compounds of formulas (Ia) and (Ib) which are PI3K-delta inhibitors, and uses for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.
PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER
-
Page/Page column 114, (2017/12/29)
The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders such as cancer, inflammatory disorders and autoimmune diseases.
